Effects of olanzapine during cognitive and emotional processing in schizophrenia: A review of functional magnetic resonance imaging findings

Abstract

Objective: Olanzapine is an atypical antipsychotic that is widely used in the treatment of schizophrenia and has shown some degree of efficacy on negative and cognitive symptoms. We aimed to review the effects of olanzapine treatment on brain regions that are directly involved in cognitive and emotional processing.Methods: We used the PubMed database to perform a bibliographic search on functional magnetic resonance imaging studies that investigated the effects of olanzapine treatment on neural activity in patients with schizophrenia during cognitive and emotional tasks.Results: Despite the high variability of tasks and analysis methods employed, the weight of the evidence was consistent with the hypothesis that olanzapine treatment is associated with a normalization of brain activity in schizophrenia. Distinctive functional changes were found in frontal cortex and cingulate cortex activity during both cognitive and emotional tasks. During emotional processing, olanzapine treatment seems to specifically regulate the activity of the striatum and limbic system. Conclusions:The results of the reviewed studies suggest that in patients with schizophrenia, olanzapine treatment might lead to a more physiological brain activity coupled with regulation of dopamine release. Future studies should further corroborate these hypotheses using larger samples and homogeneous experimental tasks.

Atypical Antipsychotics Mediate Dynamics of Intrinsic Brain Activity in Early-Stage Schizophrenia? A Preliminary Study

“…[47][48][49] After antipsychotic treatment, increased local functional activities in frontal lobe regions of the frontoparietal network and increased functional connectivity with other networks especially the limbic system have been observed. [50][51][52] As to the right inferior parietal lobule, longitudinal fMRI studies reported that the amount of ALFF in this area and the amount of FC between the bilateral IPLs significantly increased at 1-year follow-up; and increased ALFF in the IPL.R was identified with successful prediction of early treatment in schizophrenia. 53,54 Our study suggested that dynamic brain activities in the regions of frontoparietal network changed in the process of antipsychotic treatment.…”

Novel approaches to tackling emotional loss of control of eating across the weight spectrum

“…However, not all psychopharmacological drugs that help with emotional problems lead to improved control of food intake. For example, the atypical antipsychotic olanzapine which has been shown to improve emotional processing in schizophrenia (101,102) has been reported to lead to binge eating, food craving and clinically significant weight gain as a side effect (103,104) . The weight gain is most probably due to olanzapine's antihistaminergic effects in the hypothalamus which is the centre of the homoeostatic system that generates appetite and hunger (105) .…”

1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia

“…Olanzapine is an atypical antipsychotic drug that is widely used in the treatment of schizophrenia [16]. Olanzapine affects many receptors, including the dopamine D2 receptor; serotonin 5-HT2A, 5-HT2C, and 5-HT6 receptors; adrenaline α1; histamine H1; and muscarine M1-M5 [17].…”